Introduction:
Novo Nordisk plans to invest more than 42 billion Danish kroner starting in 2023. The investment is focused on expanding existing manufacturing facilities in Kalundborg, Denmark.
Features:
The expansion aims to address serious chronic diseases and cover the entire global value chain from API manufacturing to packaging.
The majority of the investment will go into increasing API capacity, with a new multi-product facility designed for flexibility in current and future processes.
GLP-1 products are included in the investment to meet future market demands.
The new API facility will have a footprint of 170,000 m2, incorporating state-of-the-art technology and a modern working environment.
Upon completion, the projects are expected to create 8,003 new jobs in the facilities. Up to 3,000 external employees will be hired during the construction phase.
The construction will focus on delivering high-quality products to patients globally in an efficient and environmentally sustainable manner.
Construction projects will take place gradually from the end of 2025 through 2029.
Specifications:
Name Novo Nordisk
Type Expansion
Year 2029
